Wegovy on Hashimoto's Disease: An Indepth GLP-1 Weight Loss Exploration

The quest for effective, lasting weight loss solutions can be daunting, more so when navigating the intricate avenues of metabolic health and GLP-1 treatments such as Wegovy. At Bolt Pharmacy, we understand this challenge. In our latest deep, dive, we explore the intersection of Wegovy and Hashimoto's, shedding light on the role of this pioneering GLP-1 medication in weight management and its relevance for those wrestling with this common thyroid disorder. Ready to unveil the potential of this metabolic health game, changer? Dive in!

Understanding Wegovy and Hashimoto's Thyroiditis

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and also for adolescents aged 12 years and above.^[1][4] The licensed dose range includes 2.4 mg and, following further MHRA authorisation, 7.2 mg weekly. It works by mimicking the action of the naturally occurring hormone GLP-1, which regulates appetite and food intake through effects on the brain's satiety centres. Wegovy slows gastric emptying, reduces hunger, and increases feelings of fullness, leading to reduced caloric intake and subsequent weight loss. The STEP clinical trials demonstrated average weight reductions of approximately 10 to 15% of body weight over 68 weeks at the 2.^[3]4 mg dose when combined with lifestyle modifications. More recent data from the STEP UP programme, examining the 7.2 mg dose, have reported higher weight-loss outcomes; patients should discuss with their clinician which dose may be appropriate for them.

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is the most common cause of hypothyroidism in the United Kingdom.^[5] This autoimmune condition occurs when the immune system produces antibodies that attack the thyroid gland, gradually destroying thyroid tissue and impairing hormone production. Patients typically present with elevated thyroid peroxidase (TPO) antibodies and thyroglobulin antibodies, alongside reduced thyroid function evidenced by elevated thyroid-stimulating hormone (TSH) and low free thyroxine (FT4) levels. Hypothyroidism affects approximately 1 to 2% of the UK population, with a significantly higher prevalence in women.

Many individuals with Hashimoto's thyroiditis experience weight gain as a consequence of the reduced metabolic rate associated with hypothyroidism. Even when adequately treated with levothyroxine replacement therapy, some patients continue to struggle with weight management. This has led to increased interest in whether medications like Wegovy might offer additional support for weight loss in this patient population, whilst raising important questions about safety and potential effects on thyroid function.

Can You Take Wegovy with Hashimoto's Disease?

Hashimoto's thyroiditis is not listed as a contraindication to Wegovy treatment in the current Summary of Product Characteristics (SmPC) approved by the MHRA.^[1] Patients with well-controlled hypothyroidism secondary to Hashimoto's disease who are stable on levothyroxine replacement therapy may be considered for Wegovy treatment, provided they meet the eligibility criteria for weight management therapy. According to NICE Technology Appraisal 875 (TA875), these criteria typically include a body mass index (BMI) of 35 kg/m² or above, or 32.5 kg/m² or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds, with at least one weight-related comorbidity. Patients should confirm the exact eligibility criteria with their prescriber, as local commissioning arrangements may apply.

The decision to prescribe Wegovy to someone with Hashimoto's thyroiditis requires careful clinical assessment. Prescribers must ensure that thyroid function is optimised and stable before initiating GLP-1 receptor agonist therapy. Uncontrolled hypothyroidism should be addressed first, as inadequate thyroid hormone replacement can contribute to weight gain and may complicate the assessment of Wegovy's effectiveness. Patients should have regular thyroid function monitoring throughout treatment, as weight loss itself can sometimes necessitate adjustments to levothyroxine dosing.

It is important to note that no direct pharmacokinetic interaction between Wegovy and levothyroxine has been established. However, because Wegovy delays gastric emptying, it may theoretically influence the absorption of orally administered medicines including levothyroxine. The SmPC notes that delayed gastric emptying should be considered for medicines with a narrow therapeutic index. For this reason, TSH monitoring is advisable, particularly after significant weight loss or if persistent gastrointestinal symptoms develop, rather than assuming levothyroxine absorption is unaffected.

Patients should be counselled about realistic expectations, potential side effects, and the importance of continued thyroid monitoring throughout treatment. Women of childbearing potential should use effective contraception while taking Wegovy and should discontinue treatment at least 2 months before a planned pregnancy, as semaglutide is not recommended during pregnancy or breastfeeding.^[1][4] For patients with diabetes, additional monitoring for diabetic retinopathy is recommended. Those on insulin or sulfonylureas may require dose adjustments to prevent hypoglycaemia.

In the NHS, Wegovy is typically prescribed through specialist weight management services (Tier 3) in accordance with NICE guidance and local commissioning arrangements.^[2]

How Wegovy May Affect Thyroid Function

The relationship between semaglutide and thyroid function has been subject to scrutiny, particularly following observations in animal studies. Rodent studies identified an increased incidence of thyroid C-cell tumours with GLP-1 receptor agonists. However, humans have significantly fewer GLP-1 receptors on thyroid C-cells compared to rodents, and extensive post-marketing surveillance and clinical trial data have not demonstrated an increased risk of medullary thyroid carcinoma in human populations. The UK SmPC for Wegovy includes a precautionary warning about these findings. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should discuss this with their prescriber before starting treatment.

For patients with Hashimoto's thyroiditis, available data do not suggest that Wegovy directly affects thyroid autoimmunity or accelerates the progression of autoimmune thyroid disease, though the evidence base specifically examining this relationship remains limited. The medication has not been shown to alter TPO antibody levels or influence the inflammatory processes underlying Hashimoto's thyroiditis based on current data; however, patients and clinicians should remain alert to any new symptoms of thyroid dysfunction during treatment.

The weight loss achieved with Wegovy may have indirect effects on thyroid hormone requirements. As body weight decreases, the dose of levothyroxine needed to maintain euthyroidism may change, typically requiring a reduction in thyroid hormone replacement. This is a physiological response to reduced body mass rather than a direct drug interaction.

Clinicians should be aware that the gastrointestinal effects of Wegovy, particularly nausea and delayed gastric emptying, could affect the absorption of levothyroxine if both medications are taken at a similar time. Current guidance recommends taking levothyroxine on an empty stomach, typically 30 to 60 minutes before breakfast, and this timing should be maintained in patients receiving Wegovy.^[5] Given levothyroxine's narrow therapeutic index, thyroid function should be reassessed if persistent gastrointestinal symptoms develop or after significant weight loss.

Monitoring and Safety Considerations

Patients with Hashimoto's thyroiditis who commence Wegovy treatment require a structured monitoring approach to ensure both safety and therapeutic effectiveness. Baseline thyroid function tests, including TSH and free T4, should be documented before initiating treatment, with the patient ideally in a euthyroid state on stable levothyroxine replacement. No specific monitoring schedule is mandated in the UK SmPC, but a pragmatic approach is to reassess thyroid function after meaningful weight loss, after any dose changes to levothyroxine, or if symptoms suggestive of thyroid dysfunction emerge. The precise weight-loss thresholds that should prompt reassessment are a matter of clinical judgement rather than a fixed rule; clinicians should use their assessment of the individual patient's circumstances. Otherwise, standard annual thyroid function monitoring is appropriate for stable patients. Patients should be educated to recognise symptoms of both hypothyroidism (fatigue, cold intolerance, constipation) and hyperthyroidism (palpitations, anxiety, tremor) that might indicate the need for levothyroxine dose modification.

Standard monitoring for Wegovy treatment applies equally to patients with Hashimoto's disease. This includes assessment of gastrointestinal tolerability, particularly during dose escalation, and vigilance for signs of pancreatitis (severe persistent abdominal pain radiating to the back). Patients should be counselled about common adverse effects including nausea, vomiting, diarrhoea, and constipation, which typically improve over time. Blood pressure and heart rate should be monitored, particularly in patients with pre-existing cardiovascular conditions, which may be more prevalent in those with longstanding hypothyroidism. GLP-1 receptor agonists are associated with a modest increase in resting heart rate.^[1][4]

Additional safety considerations include the risk of gallbladder disease (cholelithiasis, cholecystitis) and the potential for dehydration and acute kidney injury with severe gastrointestinal side effects.^[1][4] For patients with diabetes, monitoring for diabetic retinopathy is particularly important in those with pre-existing pre-proliferative or proliferative diabetic retinopathy, as rapid improvement in glycaemic control may be associated with worsening of retinopathy in this higher-risk subgroup.

Patients should be advised to contact their GP if they experience symptoms such as a lump or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath, as these warrant thyroid examination. Patients should maintain adequate hydration, particularly if experiencing gastrointestinal side effects, and should continue their levothyroxine as prescribed without interruption. Regular review of weight loss progress, typically every three months, allows assessment of treatment response. NICE TA875 recommends considering discontinuation if less than 5% weight loss is achieved after six months at the maintenance dose; patients should discuss continuation criteria with their prescriber.^[2]

Patients should report any suspected adverse reactions to the MHRA Yellow Card scheme (yellowcard.^[1]mhra.gov.uk).

Alternative Weight Management Options for Hashimoto's Patients

For patients with Hashimoto's thyroiditis who are not suitable candidates for Wegovy, or who prefer alternative approaches, several evidence-based weight management strategies exist. Optimisation of thyroid hormone replacement remains the foundation of treatment, as inadequately treated hypothyroidism significantly impairs metabolic rate and makes weight loss considerably more challenging. Regular monitoring and appropriate dose adjustment of levothyroxine to maintain TSH within the reference range (typically 0.4 to 4.0 mU/L, though individualised targets may apply) is essential before implementing additional weight management interventions.

Structured lifestyle modification programmes, as recommended by NICE guidance CG189, form the cornerstone of weight management for all patients, including those with Hashimoto's disease. These programmes typically involve dietary modification with a caloric deficit of 500 to 600 kcal per day, increased physical activity with a target of 150 to 300 minutes of moderate-intensity exercise weekly, and behavioural support to address eating patterns and psychological factors. Referral to NHS-commissioned weight management services, dietetic services, or commercial programmes with evidence of effectiveness should be considered. Some patients may benefit from very low-calorie diets (800 kcal/day) under medical supervision, particularly those with type 2 diabetes or significant obesity-related complications, as outlined in NICE CG189.

Licensed pharmacological options include orlistat, a lipase inhibitor that reduces dietary fat absorption, which may be prescribed for patients with BMI of 28 kg/m² or above with associated risk factors, or BMI of 30 kg/m² or above. It is important to note that orlistat can reduce levothyroxine absorption; the BNF recommends separating administration by at least 4 hours and monitoring thyroid function accordingly. Patients should also be counselled about gastrointestinal side effects and the need for fat-soluble vitamin supplementation. Other licensed options include liraglutide 3 mg (Saxenda), tirzepatide (Mounjaro, a dual GIP/GLP-1 receptor agonist, per NICE TA1026), and orforglipron (Foundayo), which has also received UK marketing authorisation for weight management. Eligibility and availability for each of these medicines is subject to local commissioning arrangements and NICE guidance, and the list of authorised options may evolve; patients should discuss current options with their prescriber.

For patients with severe obesity (BMI of 40 kg/m² or above, or 35 kg/m² or above with comorbidities) who have not achieved adequate weight loss with non-surgical interventions, bariatric surgery may be considered following specialist assessment, as outlined in NICE CG189. Procedures such as gastric bypass or sleeve gastrectomy have demonstrated significant long-term weight loss and improvement in obesity-related comorbidities, though patients require lifelong monitoring including thyroid function assessment, as malabsorption may affect levothyroxine requirements. All weight management approaches should be individualised, taking into account patient preferences, comorbidities, and the multifactorial nature of weight regulation in Hashimoto's thyroiditis.

Frequently Asked Questions